Boehringer Ingelheim introduces DiaTEC, a new and proprietary purification technology for Ingelvac CircoFLEX®

Ingelheim, Germany, Fri, 01/03/2020 - 09:00

Ingelvac CircoFLEX^® was the first PCV2 vaccine that could be freshly mixed with an M hyo vaccine to address two critical swine pathogens in one injection.
With DiaTEC, a new and proprietary diafiltration technology, Ingelvac CircoFLEX^® becomes the first and only non-virucidal PCV2 vaccine for improved capabilities to be freshly mixed on farm.
Since its launch, Ingelvac CircoFLEX^® has been used to protect 3 billion pigs in more than 68 countries around the world, based on vaccine sales.

Ingelheim, Germany, 3 January 2020 – When launched, Ingelvac CircoFLEX^® was the first PCV2 vaccine that could be freshly mixed with an M hyo vaccine and is still considered one of the most revolutionary PCV2 vaccines on the market. Due to its unique features, it has built a reputation for providing safe, effective control of porcine circovirus associated disease (PCVAD) in pigs three weeks of age or older from a single dose.

Eleven years after launching Ingelvac CircoFLEX^®, researchers of Boehringer Ingelheim developed a process, named DiaTEC, within the current outline of production that removes residual cell media components from the VLPs (virus like particles) to obtain a highly immunogenic and non-virucidal vaccine.

The same diafiltration process is also applied in the production of Reprocyc ParvoFLEX, another vaccine from Boehringer Ingelheim that can be mixed with the modified live vaccine Reprocyc PRRS EU which was launched in October 2019.

Eva Joras, Global Brand Manager at Boehringer Ingelheim, shared: “I am really proud that we continuously invest in our research and development to further improve our leading products to address our customers’ needs.”

The CVMP (Committee for Medicinal Products for Veterinary Use) granted the positive opinion¹ for this type II grouped variation application in May 2019 and as of January 2020 onwards Ingelvac CircoFLEX^®, manufactured with the new diafiltration process, DiaTEC, will be launched in several differing packaging sizes.

With this new diafiltration technology, the color of the vaccine has changed to a clear suspension while Ingelvac CircoFLEX retains all of its previous label claims, efficacy and safety profile. To enhance the differentiation of the product at this time, the packaging design has been updated to a more modern and clean design.

Boehringer Ingelheim Animal Health Business Unit

Boehringer Ingelheim is the second largest animal health business in the world, with net sales of almost 4 billion euros in 2018 and presence in more than 150 markets.

Across the globe, our 10,000 employees create the future of animal wellbeing through their daily work. We believe in prevention over treatment and therefore, we focus on developing innovative solutions in the field of vaccines, parasiticides and therapeutics. With a large portfolio of advanced, preventive healthcare products, tools and services, we support our customers in taking care of the health of their animals.

For more information visit: www.boehringer-ingelheim.com/animal-health/overview.

Boehringer Ingelheim

Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros, corresponded to 18.1 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: https://annualreport.boehringer-ingelheim.com.

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.